. 2015 Jun 19;6(17):14744–14753. doi: 10.18632/oncotarget.4539

Table 1. Clinical trails with tareted therapies, alone or in combination with chemotherapy, in CC.

THERAPEUTIC REGIMEN	TARGET	PHASE	N° OF PATIENTS	END-POINTS: results (months)
SORAFENIB ⁽⁵⁾	VEGFR-2/-3, PDGFR-β, B-Raf, C-Raf	II	46	PFS: 2.3 OS: 4.4
SUNITINIB ⁽⁶⁾	VEGFR, PDGFR and KIT	II	56	TTP: 1.7
LAPATINIB ⁽⁷⁾	EGFR, Her2/Neu	II	57	PFS: 1.8 OS: 5.2
SELUMETINIB ⁽⁸⁾	MEK1, MEK2	II	88	PFS: 3.7 OS: 9.8
GEMOX + BEVACIZUMAB ⁽⁹⁾	VEGF	II	35	PFS : 7.0
GEMOX + CETUXIMAB ⁽¹⁰⁾	EGFR	II	76	PFS: 6.1 OS: 11.0
GEMOX + PANITUMUMAB ⁽¹¹⁾	EGFR	II	46	PFS: 8.3 OS: 10.0
GEMOX + ERLOTINIB ⁽¹²⁾	EGFR	III	135	PFS: 5.8 OS: 9.5
DOCETAXEL + ERLOTINIB ⁽¹³⁾	EGFR	II	11	OS: 5.7
GEMCITABINE + CETUXIMAB ⁽¹⁴⁾	EGFR	II	44	OS: 13.5
BEVACIZUMAB + ERLOTINIB ⁽¹⁵⁾	VEGF, EGFR	II	49	OS: 9.9 TTP: 4.4
SORAFENIB + ERLOTINIB ⁽¹⁶⁾	VEGFR-2/-3, PDGFR-β, B-Raf, C-Raf, EGFR	II	34	PFS: 2.0 OS: 6.0
CISPLATIN/GEMCITABINE + SORAFENIB ⁽¹⁷⁾	VEGFR-2/-3, PDGFR-β, B-Raf, C-Raf	II	39	PFS: 6.5 OS: 14.4

Abbreviations: GEMOX, gemcitabine and oxaliplatin; PFS, progression-free survival; OS, overall survival; TTP, time to progression.